Dr. Yan Qin 秦燕
Chief Physician
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of lymphoma, with additional experience in lung, breast, gastrointestinal, reproductive system, and head and neck tumors.
Dr. Qin graduated from Suzhou Medical College in 1993 and earned a clinical oncology doctorate from Peking Union Medical College in 2006. Since 1999, Dr. Qin has worked in medical oncology, focusing on chemotherapy, biological, and endocrine therapies. Dr. Qin has published over 10 papers and contributed to more than 10 monographs.
Name order: in Chinese the family name comes first (Qin Yan). Papers usually list the name as Yan Qin or Qin Y.
Selected publications
66 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Cancer, 2024 (first author): Long-term outcomes with HLX01 (HanliKang(®)), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study. PubMed 38267866
- Eur J Haematol, 2023 (first author): Efficacy and safety of PD-1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients. PubMed 37294015
- J Cancer Res Clin Oncol, 2023 (first author): MYD88(L265P) and MYD88(other) variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma. PubMed 37093346
- Cancer Biol Med, 2021 (first author): Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP. PubMed 34806851
- Cancer Manag Res, 2020 (first author): Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients. PubMed 33204162
- Cancer Commun (Lond), 2018 (first author): Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial. PubMed 29843792
- Chin J Cancer Res, 2017 (first author): A phase I study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF) in patients with standard-dose chemotherapy-induced neutropenia. PubMed 29142459
- Ai Zheng, 2006 (first author): [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil]. PubMed 16613685
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion